Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 436 entries
View as:

Construction of a Prediction Model for Metachronous Colorectal Adenoma

Phase: N/A Priority: Normal
NCT ID: NCT05183438 Org: User:
Start: 05/01/21 End: 12/01/22 Due: 12/01/23

Application of Electronic Endoscope in Fetal Distress

Phase: N/A Priority: Normal
NCT ID: NCT06608654 Org: User:
Start: 10/01/24 End: 08/25/26 Due: 08/25/27

Penehyclidine for PONV Prophylaxis After Strabismus Surgery

Phase: N/A Priority: Normal
NCT ID: NCT04054479 Org: User:
Start: 07/20/19 End: 11/01/19 Due: 11/01/20

A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05105750 Org: User:
Start: 10/15/21 End: 03/20/22 Due: 03/20/23

Intervention for the Elderly With Malnutrition, Hidden Hunger and Low Skeletal Muscle Mass

Phase: N/A Priority: Normal
NCT ID: NCT03648580 Org: User:
Start: 05/20/17 End: 06/30/19 Due: 06/30/20

Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus

Phase: N/A Priority: Normal
NCT ID: NCT05978791 Org: User:
Start: 10/11/23 End: 06/30/24 Due: 06/30/25

The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy

Phase: N/A Priority: Normal
NCT ID: NCT05356156 Org: User:
Start: 04/30/22 End: 03/31/27 Due: 03/31/28

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05764941 Org: User:
Start: 01/01/20 End: 03/31/24 Due: 03/31/25

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04899128 Org: User:
Start: 08/01/18 End: 06/30/21 Due: 06/30/22

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06698692 Org: User:
Start: 04/02/24 End: 04/02/25 Due: 04/02/26

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06472479 Org: User:
Start: 07/01/24 End: 10/12/29 Due: 10/12/30

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Phase: N/A Priority: Normal
NCT ID: NCT06108596 Org: User:
Start: 10/21/23 End: 12/31/24 Due: 12/31/25

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06563869 Org: User:
Start: 02/02/24 End: 11/22/26 Due: 11/22/27

Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT06542653 Org: User:
Start: 09/17/23 End: 09/17/25 Due: 09/17/26

Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms

Phase: N/A Priority: Normal
NCT ID: NCT06826144 Org: User:
Start: 02/20/25 End: 06/01/26 Due: 06/01/27

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT06015464 Org: User:
Start: 09/01/23 End: 07/30/25 Due: 07/30/26

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06125834 Org: User:
Start: 06/01/23 End: 05/31/26 Due: 05/31/27

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06977828 Org: User:
Start: 05/07/25 End: 12/31/28 Due: 12/31/29

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT06770296 Org: User:
Start: 11/01/24 End: 11/01/28 Due: 11/01/29

The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections

Phase: N/A Priority: Normal
NCT ID: NCT06990126 Org: User:
Start: 03/01/24 End: 06/30/25 Due: 06/30/26

Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT02912052 Org: User:
Start: 10/31/16 End: 10/31/23 Due: 10/31/24

Omission of ALND in Breast Cancer Patients With Axillary pCR

Phase: N/A Priority: Normal
NCT ID: NCT05939830 Org: User:
Start: 09/11/23 End: 07/31/26 Due: 07/31/27

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05430347 Org: User:
Start: 04/15/23 End: 09/30/25 Due: 09/30/26

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06279767 Org: User:
Start: 07/01/22 End: 07/31/25 Due: 07/31/26

Establishment and Validation of a Predictive Model for the Risk of Colorectal Advanced Adenomas

Phase: N/A Priority: Normal
NCT ID: NCT05152082 Org: User:
Start: 06/01/21 End: 12/01/22 Due: 12/01/23